Glycan recognition by lectins initiates clinically relevant processes such as toxin binding or tumor spread. Thus, the development of potent inhibitors has a medical perspective. Toward this goal, we report the synthesis of both rigid and flexible bivalent lactosides on scaffolds that include secondary and tertiary terephthalamides and N,N 0 -diglucosylterephthalamides. Construction of these compounds involved Schmidt-Michel glycosidation, and amide coupling or Ugi reactions of relevant glycosyl amines in key steps. A glycocluster based on a rigid glycophane was also prepared from coupling of a glucuronic acid derivative and p-xylylenediamine with subsequent ring-closing metathesis. Finally, a more flexible bivalent lactoside was produced from lactosyl azide with use of the copper-catalyzed azide-alkyne cycloaddition. Distances between lactose residues were analyzed computationally as were their orientations for the relatively rigid subset of compounds. Distinct spacing properties were revealed by varying the structure of the scaffold or by varying the location of the lactose residue on the scaffold. To relate these features to bioactivity a plant toxin and human adhesion/growth-regulatory galectins were used as sensors in three types of assay, i.e. measuring agglutination of erythrocytes, binding to glycans of a surface-immobilized glycoprotein, or binding to human cells. Methodologically, the common hemeagglutination assay was found to be considerably less sensitive than both solid-phase and cell assays. The bivalent compounds were less effective at interfering with glycoprotein binding to the plant toxin than to human lectins. Significantly, a constrained compound was identified that displayed selectivity in its inhibitory potency between galectin-3 and its proteolytically processed form. Conversely, compounds with a high degree of flexibility showed notable ability to protect human cells from plant toxin binding. The applied conjugation chemistry thus is compatible with the long-term aim to produce potent and selective lectin inhibitors.
Introduction
Carbohydrates have ideal properties to generate an unrivalled number of oligomers. They are capable of engaging in molecular recognition events in biological systems, underlying the concept of the sugar code. 1 Indeed, glycan chains presented on cell surface glycoconjugates are versatile biochemical signals by serving as direct contact sites for receptors (lectins) that bind to carbohydrates (trans-interactions) and as potent molecular switches regulating aspects of protein accessibility and functionality (cis-interactions). 1, 2 Besides the structure of the headgroup of a glycan chain its presentation and local density govern the affinity in intermolecular interactions, as recently revealed in the case of physiological core substitutions in N-glycans which trigger significant alterations in glycan conformations and, importantly, in lectin affinity. 3 Distinct changes in glycan display including microdomain formation in natural systems can thus lead to induction of cellular responses such as anoikis/ apoptosis or autoimmune suppression via lectin binding. 4 To underscore the emerging clinical relevance a tumor suppressor and responses in inflammation can apparently work on this level by remodelling cell surface glycan profiles and even lectin expression to result in host defense/antimalignancy effects. 4c,d Clinically disadvantageous, lectin binding to glycans is also involved in disease progression. Herewith, it gives an incentive for drug design. Considering the multiple, medically relevant activities of cell surface glycans in concert with lectins in regulating, for example, adhesion, migration, proliferation, or tissue invasion or serving as docking sites for plant/bacterial toxins, 1 it clearly is an attractive goal to develop new molecules which can efficiently interfere with binding of certain effectors to cell surface glycans.
Of current interest to us toward this goal is a series of bivalent glycoclusters of varying degree of scaffold flexibility, altering ligand spacing with a view to profiling the structure-bioactivity relationships. As a first step, we recently described the synthesis and biological evaluation of a series of bivalent mannosides based on terephthalamide and glycocyclophane scaffolds, the latter being derived from phenylene-1,4-diamines. 5 Initial testing for bioactivity with leguminous lectins in cell-based assays showed that presentation of the mannose residues on a rigid macrocyclic scaffold can lead to enhanced inhibitory capacity. 5 Evidently, the mannose moieties maintained ligand-binding capacity for the tested plant lectins. Thus, this proof-of-principle result encourages further efforts with a headgroup different from that of mannose and medically relevant lectins.
Due to its positioning at branch ends of glycan chains and frequent involvement in lectin binding β-galactose satisfies the requirement for biological relevance. 1, 2 Testing of bivalent scaffolds presenting β-galactosides (e.g., lactosides) in assays with a biohazardous toxin and with human lectins was therefore envisaged to provide a medical perspective. Consequently, we were interested to establish synthetic routes that would allow bivalent lactosides based on macrocyclic and terephthalamide scaffolds to be generated. As follows, the syntheses of ligands (Chart 1) with β-lactose conjugated to terephthalamide scaffolds 6 (1) (2) , N 0 ,N 0 -diglucosylterephthalamides (3) (4) (5) , and a rigid macrocyclic glycocyclophane 8 are presented. Preparations of 6 and 7 with increased flexibility compared to the conformationally arrested compound 8 are included as was the generation of the triazole derivative 9. Geometrical aspects of presentation of the β-lactose units in the more rigid compounds were then comparatively inferred by computational methods.
Bioactivity of the sugar headgroup and the impact of structural properties were next examined in the commonly used hemeagglutination test and also in a solid-phase binding assay. The latter assay was based on evaluating the ability of synthetic compounds to inhibit binding of lectins to a natural glycoprotein (asialofetuin (ASF) with three N-glycosylation sites preferentially occupied by complex-type triantennary N-glycans). Since any clinical application would be based on impairing lectin binding to cells, we also determined the extent of lectin binding to native human cells as a function of the presence of the new compounds. Lectin selection for the assays was based on the aim to protect cells from toxicity, in addition to evaluating the potential of the test panel to interfere with progression of disease in malignancy due to activity of distinct adhesion/ growth-regulatory galectins. 7 In detail, the binding of Viscum album agglutinin (VAA) and human galectins-3 and -4 to the surface-presented glycoprotein was monitored in the absence/ presence of a test compound, using free lactose as an internal standard of inhibitory potency. Galectin-3 has two special features in this respect: it can pentamerize in the presence of a multivalent ligand and it is physiologically truncated by matrix metalloproteinases-2/-9 to yield a trimmed (truncated) version with diminished propensity for oligomer formation.
8 Galectin-3 and its truncated derivative were thus tested to reveal any difference in sensitivity to the glycocompounds and a selective inhibitor was identified. The obtained results demonstrate the bioactivity of this panel of glycoclusters as well as reveal a notable influence of assay system, compound, lectin, and matrix properties on inhibitory potency.
Results and Discussion
Synthesis of Glycoclusters. Synthetic routes were first established to produce 1-9. It was envisaged that 1 and 2 could be prepared from lactosyl amine 10. Fittingly, coupling of 10 with terephthaloyl chloride in the presence of triethylamine and subsequent Zempl en deacetylation gave 1. Since the glycosyl amine 10 also contained a small amount of the R-anomer, a mixture of diamides was obtained from the coupling reaction. The bivalent compounds 11 and a lesser amount of 12 containing R-glycosyl amides were thus also obtained after HPLC-based separation of the deacetylated diamide mixture (Scheme 1). Next, the Ugi reaction of 10 in the presence of formaldehyde, methyl isocyanoacetate, and terephthalic acid and subsequent Zempl en deacetylation resulted in the bivalent compound 2. It differs from 1 in that tertiary amides are present as opposed to secondary amides.
In the next step, approaches to bivalent lactosides based on N,N 0 -diglucopyranosylterephthalamide scaffolds were studied. The Schmidt-Michel glycoside coupling reaction of trichloroacetimidate 14 with 13 with TMSOTf as catalyst and subsequent reaction of the trisaccharide product with SnCl 4 and TMSN 3 generated azide 15. Catalytic hydrogenation led to the glycosyl amine and subsequent coupling with terephthaloyl chloride followed by deacetylation as before gave 3 where the lactosyl units are attached to both 6-O atoms of the scaffold (Scheme 2). CHART 1. β-Lactose-Based Glycoclusters Cancer Invest. 2001, 19, 114-126. (c) 
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The synthesis of 4 was achieved via the glucopyranoside 16. Glycosidation of the acetylated lactosyl trichloroacetimidate donor 14 opened the way to the desired trisaccharide 17. Acetolysis gave the glycosyl acetate derivative and its subsequent reaction with azidotrimethylsilane in the presence of SnCl 4 the desired β-azide 18. Reaction of 18 as described for 15 produced bivalent compound 4 (Scheme 3). The lactose units are covalently linked to the two 4-O atoms of the N,N 0 -diglucosylterephthalamide scaffold.
To prepare other analogues which would be available by using the 3-O atoms of the scaffold as an attachment site, a respective strategy was developed. Toward this aim, glycosidation reactions of the glycosyl acceptor 20 with donor 14 were not successful, which contrasted with what we observed for the other acceptors (Schemes 2 and 3). An orthoester byproduct, often detected in glycosidation reactions, was obtained instead of the desired glycosidic product. To address this problem the benzoylated lactosyl trichloroacetimidate 19 was prepared and its reaction with 20 investigated, leading to the successful formation of the desired β-glycoside 21 in good yield. Hydrolysis of the acetonide groups, subsequent acetylation followed by reaction of the product with SnCl 4 and TMSN 3 , and then catalytic hydrogenation gave the amine 22. Treatment of amine 22 with terephthaloyl chloride as before and ensuing removal of the acyl protecting groups resulted in 5 (Scheme 4).
With this series of bivalent lactosides in hand we next added compounds to the panel based on scaffolds that were amides of glucuronic acid. Consequently, the acceptor 23, which we had used previously to prepare mannosides, on reaction with acetylated lactose donor 14 gave the undesired orthoester 24. Application of the benzoylated donor 19 in the glycosidation yielded the suitable trisaccharide intermediate, which was then converted to 25 after selective removal of the allyl ester with Pd(0) catalysis (Scheme 5).
9 In our previous work we had synthesized the bivalent mannosides via coupling of a glucuronic acid derivative with phenylene-1,4-diamine. The products of coupling of phenylene-1,4-diamine to the acid 25 were analyzed indicating that only one SCHEME 1. Synthesis of 1, 2, and 11 SCHEME 2. Synthesis of 3 (9) Kunz, H.; Waldmann, H. Angew. Chem., Int. Ed. 1984, 23, 71-72. trisaccharide residue had been added to one amine group (Scheme 5). It is presumed that formation of the first amide group leads to a reduction in nucleophilicity of the second amine group of the phenylene-1,4-diamine residue precluding formation of a second amide. We thus investigated the preparation of diamides from 1,4-di(aminomethyl)benzene (p-xylylenediamine), where electron-withdrawing effects were expected to have been lessened. Conversion of 25 to its acid chloride with a view to using this for the amide synthesis led to the formation of the glycosyl chloride 26, tentatively explained by the mechanistic proposal outlined in Scheme 6. The activation of O-glycosidic linkages by manipulation of remote carboxylic acid groups has already been delineated and favorably utilized in glycosidation reactions.
10 Herein, a glycosyl carbenium ion is proposed to be generated via the acid chloride, the former which is subsequently trapped by chloride ion (Scheme 6). Eventually, the desired coupling reaction en route to the diamide was achieved by activation of the acid 25 with HOBt, DIPEA, and HATU in the presence of the p-xylylenediamine. Removal of the acetate and benzoate protecting groups gave the flexible divalent compound 6 (Scheme 5).
Having established conditions for the formation of 6, we next worked toward the synthesis of bivalent lactosides based on a glycocyclophane scaffold derived from the pxylylenediamine. The acceptor 28 was therefore prepared from 27 as described previously 5 and its reaction with 19 and subsequent chemoselective deallylation with Pd(0) gave 29. Reaction of 29 with p-xylylenediamine in the presence of HOBt, HATU, and DIPEA generated the protected divalent compound 30 (Scheme 7), a suitable precursor for ring closure metathesis (RCM). 
The subsequent RCM of 30 with the Grubbs-I catalyst gave a mixture of macrocyclic isomers containing E-and Z-alkene groups, and unreacted 30 was also recovered. Hydrogenation of the mixture produced 31 and 32. These compounds were readily separated by chromatography. The removal of the protecting groups from 31 and 32 was the last step of the route providing the acyclic derivative 7 and the rigid macrocyclic derivative 8 (Scheme 8).
Finally, the bivalent lactoside 9 was prepared from 34 and the lactosyl azide 33 with the copper-catalyzed azide-alkyne cycloaddition reaction.
11 To facilitate purification of 9, the product from the click reaction was acetylated, purified by chromatography, and subsequently deacetylated (Scheme 9). Having herewith completed the synthetic part, we next proceeded to calculate geometrical aspects of ligand positioning in the bivalent systems.
Analysis of Ligand Spacing. The use of rigid scaffolds presenting ligands can avoid entropic penalties that occur upon binding to a receptor, particularly if they are preorganized into a constellation favorable for binding. If the two sugar headgroups react with different lectin molecules, then orientation and spacing may also have a bearing on bioactivity. The aim to relate structure to function explains our interest to calculate interligand spatial relationships for the bivalent lactosides. At the outset, the panel of compounds was separated into two categories based on their relative flexibility. Two parameters were chosen to define the interligand spacing: the distances between the two Glc C-1 atoms of the lactose residues was defined as the interlactose distance whereas the torsion Gal C4-Glc C1-Glc C1-Gal C4 corresponding to the lactose residues was defined as the lactose orientation (see Figure 2D ). Since the β-lactosides 1-5 and 8 were judged to have fewer degrees of freedom when compared to 6, 7, and 9, conformational analysis was focused on the former structures. When calculating the spatial relationships between the two lactose residues in compounds 1-5 and 8, we used Macromodel for model building and all subsequent computations.
12 Experimentally observed SCHEME 5. Synthesis of 6 SCHEME 6. Proposed Route of Formation of 26 SCHEME 7. Synthesis of 30 glycosidic torsion angles (φ = O5-C1-O1-Cx; ψ = C1-O1-Cx-C(xþ1); ω = O5-C5-C6-O1) were used to guide the building 13 of model structures establishing the structure from which conformational searching commenced. In detail, the glycosidic torsions from a published crystal structure of a β-lactoside 14 (φ=-88; ψ=-161) defined the corresponding torsions in the lactose residues of the model structures. To complete the models of 3-5 additional torsions for the glycosidic linkage between the glucose residue of the scaffold and the glucose residue of the lactose needed to be defined; the φ, ψ, and ω values were again obtained from Xray crystal structural data. For the β-D-Glc(1-6)-β-D-Glc linkage in 3 the φ, ψ, and ω were -59°, -155°, and -61°, respectively;
15 for the β-D-Glc(1-4)-β-D-Glc linkage in 4, the φ and ψ used were -76°and 132°;
16 for the β-D-Glc(1-3)-β-DGlc linkage in 4, the φ and ψ used were -94°and 78°.
17
Equally relevant studies on the structural orientations of N-glycosyl benzamides had been carried out previously, providing a basis to define the preferred torsional parameters SCHEME 8. Synthesis of 7 and 8 SCHEME 9. Synthesis of 9 1992, 237, 33-42. for glycosyl amide residues of 1-5. Thus N-glycosyl benzamides that contain secondary amides adopt the Z-configuration (or trans amide), whereas those that are tertiary amides prefer the E-configuration (cis amide). The glycosyl amide torsion defined by H1-C1-N-H was constrained at a value of 171°(anti-conformation); this is close to the average of the angles observed (168.2°to 175.0°) in a number of X-ray crystal structures of related secondary glycosyl amides and supported by 1 H NMR (J H1-NH ≈ 9.0 Hz) in solution. 18 The two carbonyl groups of the terephthalamide residues were constructed with a trans coplanar arrangement (dihedral defined by OdC;CdO 180 ( 60°) for 1 and 3-5. During modeling of 2, the aromatic groups were not coplanar with the carbonyl groups for reasons discussed previously.
6 All these parameters combined facilitated the establishment of the initial models of 1-5. A starting structure of the glycocyclophane derivative 8 was also established and together with the models of 1, 2, and 3-5 was used to start systematic conformational searches; for 1 and 2 stochastic molecular dynamics was also explored. The AMBER (assisted model building with energy refinement) force field and the GB/SA continuum for water in Macromodel were generally applied. For the conformational searches all isomers within 12 kJ/mol of the global minimum were retained and used in the subsequent analysis. The terephthalamides containing secondary amides (1, (3) (4) (5) consistently gave low-energy structures where the carbonyl groups of the terephthalamides were either cis or trans (shown for low-energy structures of 1 and 3 in Figure 1 ). This torsion, defined by OdC;CdO atoms of the terephthalamide residue, is referred to as the terephthalamide torsion subsequently. Our analysis (Figure 2A ,C) for all the lowenergy structures generated showed how the terephtalamide torsion affected interlactose distance and lactose orientation. For 1 the interlactose distance was constrained between 10.1 and 10.4 Å for all low-energy structures. Increased flexibility was observed for 3 where interlactose distance ranged from 13.0 to 18.8 Å , whereas intermediate flexibility was observed for 4 (19.1-20.7 Å ) and 5 (16.3-17.2 and 18.0-18.4 Å ). In all low-energy conformers of 8 (Figure 1 ), which was the most rigid structure, the glucuronic acid residues inherent in the macrocycle adopted a cis relationship (or a U-shape) with respect to the benzene residue, as was also found in related macrocycles derived from phenylene-1,4-diamine. The interlactose distance was firmly constrained between 15.4 and 15.5 Å in 8. Conformational searches on 2 led to highly folded low-energy structures which were deemed unlikely to be accessed by lectins and which possibly were artifacts. Thus, a stochastic molecular dynamics simulation instead explored the conformational space for 2 and commenced from a structure where the carbonyl groups of the terephthalamide residue were trans (OdC;CdO torsion ∼90°). In the molecular dynamics runs a temperature of 300 K, time step of 1.5 fs, equilibration time of 1.0 ps, and simulation time of 2 ns were set and 500 structures were sampled over the duration of the simulation. The result derived from the sampled structures is also included in Figure 2 . The interlactose distance was found to be constrained between 7.2 and 8.1 Å for 2. Similar stochastic molecular dynamics simulations were also performed for 1 (not shown), coming up with reasonable correlations between the interlactose distances and lactose orientations of structures generated in the dynamics simulations and in conformational searching.
In addition, plots were generated for each set of conformers showing the relationship between interlactose distance and lactose orientation ( Figure 2B ), which further demonstrated the unique spatial profile for each molecule. This analysis was also useful to depict the constraints imposed on each of the molecules. For example, for 5 there are two lowenergy clusters: the first corresponds to a set of conformers with a lactose orientation that varies from -50°to -22°and a corresponding interlactose distance of 16.3-17.2 Å ; the second cluster is a set of conformers where the lactose orientation varies between 84°and 139°and a corresponding interlactose distance of 18.0-18.4 Å . In general, the analysis shows that, while the subset of glycoclusters can adopt a range of interlactose distances (∼7-21 Å ) as well as a very large range of interlactose orientations from -180°to þ180°, not all regions of space definable by both these parameters are occupied. Running a similar conformational search for the triazole derivative 9 indicated that it should be more flexible than the selected rigid subset. For 9 the interlactose distance was shown to vary from 9 to 17 Å and the lactose orientation varied between -165°and þ 165°, suggesting it can have spacing arrangements not accessible to 1-5 and 8. This would be the case also for 6 and 7. If bioactive, it will thus be a key question whether flexible compounds such as 6 and 9 or less flexible substances will exhibit relatively higher potency for interfering with lectin activity. Having prepared the panel of glycoclusters and examined their conformational properties, the next step was therefore to ascertain the implied bioactivity of the carbohydrate headgroups and, if possible, to establish structure-activity profiles for inhibitory lectin binding.
Inhibition Studies. At the outset, we performed hemeagglutination tests classical to lectin research.
1 Using trypsintreated, glutaraldehyde-fixed rabbit erythrocytes, the activity of lactose or the glycoclusters was assessed for their ability to inhibit lectin-mediated hemeagglutination in a total volume of 50 μL. Lactose (but not controls such as mannose) was effective at blocking lectin activity at concentrations of 2 and 0.8 mM, respectively, when using the plant toxin (25 ng/ 50 μL) and galectin-3 (2 μg/50 μL). The sugar units in compound 9 matched the activity of free lactose but no inhibitory activity was seen for any other test substance up to a concentration of 25 mM (given as sugar concentration). To infer whether the setting of this assay, where cell agglutination was the measured parameter, may have a bearing on sensitivity to pick up compound activity, we next employed an assay that measured the ability of a glycocluster to inhibit binding, in this case to a surface-immobilized glycoprotein. In the solid-phase setting, the extent of the lectin-glycoprotein interaction and inhibition thereof are determined spectrophotometrically.
To set up optimal conditions for this assay the coating density and lectin concentration were systematically tested until the dependence of signal intensity on lectin concentration was in the linear range. The signal was shown to be consistently dependent on the protein-carbohydrate interaction, as revealed by haptenic inhibition with lactose. Under these subsaturating conditions, the sensitivity to determine inhibitory potency of the synthetic compounds was optimal. As seen in Figure 3 , glycoclusters from the synthetic panel blocked lectin binding to the glycans of the glycoprotein with higher efficiency than free lactose. Obviously, the conjugation chemistry did not impair the bioactivity, and attachment to a scaffold could enhance the inhibitory potency of lactose. Titrations were used to determine the concentration required to reach 50% inhibition (IC 50 ; Table 1 ). The inhibitory effects were most pronounced for the proteolytically truncated form of human galectin-3 and for galectin-4, when using ASF as matrix. The minimal interlactose distance observed for compound 2 translated into potent inhibition in these two cases. In comparison, the plant toxin (VAA), where the two readily accessible lectin sites of the 2γ subdomains are separated by 87 Å , 7g showed no notable response to cluster formation or scaffold rigidification. Even more important, the unprocessed form of galectin-3 was much less sensitive to the presence of 2. Thus, inhibitory capacity depended on the type of lectin and scaffold used to present the lactose as well as lectin-site presentation (e. g., galectin-3 vs. truncated galectin-3). It might also depend on matrix properties. To address this issue the solid-phase assay was carried out with a glycoprotein with only one N-glycosylation site, this strictly bearing bi-instead of triantennary Nglycans, i.e. serum amyloid P component (SAP). The effect of using SAP as the matrix was thus to reduce the glycan microdensity. In this case, enhancements of inhibitory activity were measured for galectin-3, with all compounds being at least 5-fold more active than free lactose and substances 4-9 being the most potent reaching up to a 50-fold activity increase. In contrast, toxin binding remained less susceptible. Considering this aspect and attaining increased physiological relevance, we next probed binding of the plant toxin and galectin-3 to the surface of native cells, in this case human Blymphoblastoid Croco II cells. Interference by the glycoclusters was quantified.
All measurements were routinely performed with aliquots of the same cell batch and passage, prolonged culture periods with inevitable impact on cell features were hereby avoided. The extent of carbohydrate-dependent cell binding was experimentally determined by fluorescent staining in FACScan analysis, obtaining the percentage of positive cells and signal intensity on a logarithmic scale as read-out, as presented in Figure 4 . The binding of the labeled lectin to the cell surface shifted the curve representing the staining profile of each lectin-exposed cell population from the position of the control (given as the shaded area in each figure) , and the presence of an effective inhibitor will move the curve back into the direction of the control. Optimal conditions with a subsaturating lectin concentration and a lactose concentration in the linear range of signal intensity were identified first by systematic testing (Figure 4A,B) . Routinely, measurements were done in triplicates with up to three independent series. As exemplarily illustrated in Figure 4C -F, compounds 6 and 9 were considerably more active than free lactose to block plant toxin binding to the cells, which correlated reasonably well with the binding data obtained from the solid-phase assay. In the case of galectin-3, the measurements (scans not shown) came up with a broadly similar trend as observed in the solidphase assay, and 8 was less potent than 6 and 9 in this setting. In detail, five compounds superseded the activity of free lactose. With standard deviations of less than 11%, the difference between the flexible and rigid compounds 6 and 8 seen in solid-phase assays remained with respective values of 34.8 vs. 39.8 relative to 49.9 for lactose in mean intensity (at 0.5 mM sugar concentration), whereas compounds 2 and 3 were less potent than lactose with intensity values of 51.8 and 61.6. Compound 9 also resulted in marked inhibition to 35.1 in intensity. Thus, the substances 6 and 9 are particularly effective to reduce lectin association to this type of native human cells. Flexibility of bivalent compounds thus appears to be a favorable factor when aiming to inhibit the toxin and galectin-3.
Summary and Conclusions
We have reported the synthesis of different types of bivalent lactosides based on terephthalamides and glycocyclophanes as well as other analogues. Rather rigid Table 1 for IC 50 values). The inhibitor concentration given is normalized to lactose for direct comparison. Assays were routinely done in triplicates for up to five independent series with standard deviations not exceeding 17%. compounds were characterized computationally with respect to geometry of presentation of the sugar headgroups. Bioactivity of the glycocompounds was systematically tested in hemeagglutination as well as solid-phase and cell assays. Haemagglutination as a test system proved rather insensitive, where only one compound was found to be active as inhibitor of lectin-dependent erythrocyte agglutination. In contrast, measuring the extent of lectin binding to glycoproteins on a solid phase or on cell surfaces as the experimental end point disclosed remarkable bioactivity. These experiments added substantial support to the concept that both terephthalamide and glycocyclophanes 19 can be considered as suitable scaffolds for presentation of carbohydrate ligands. 20, 21 Either introducing structural changes to a scaffold (e.g., compare 1, 2, and 8) or strategically grafting a lactose residue to different locations of a common scaffold (compare 3-5) led to diverse interlactose spacing. These changes in geometry can apparently factor into the observed alterations for inhibitory capacity, especially for the truncated form of galectin-3 and the tandem-repeat-type galectin (galectin-4). In addition, increasing rigidity of a scaffold by macrocyclisation (6 and 7 < 8) also affects lectin reactivity to bivalent scaffolds, with a trend toward activity loss in assays with the plant toxin as compounds become more rigid. Protection of cells from association with the plant toxin was best achieved with the flexible compound 6, in accord with the data from solid-phase assays. The relatively increased activity for the flexible derivatives could be due to their ability to access favorable ligand spacings not possible for the more rigid compounds. In addition, the chemical characteristics of the spacer and its environment may also play a role in enhancing binding properties, as does the choice of glycoprotein used as matrix and the cell surface, rendering it difficult to draw unambiguous a priori conclusions.
The structural analysis indicates that it is unlikely that compounds exert their inhibition by binding to multiple carbohydrate recognition sites on one lectin as would be the case, for example, for the glycoside cluster effect of triantennary N-glycans homing in on the hepatic asialoglycoprotein receptor; it seems more likely that the effects would be due to bivalent compounds binding to more than one lectin molecule, possibly promoting lectin clustering. At any rate, the sugar headgroups maintained bioactivity after conjugation and attained differential reactivity to the tested human lectins, as seen especially for compound 2 and the truncated form of galectin-3 and galectin-4 with a more than 10-fold and even higher increase of sugar activity relative to free lactose. This gain in activity seen in solid-phase assays could be due to constraint of the lactose residues into a favorable presentation at minimal interlactose distance, a benefit of using a scaffold based on the tertiary terephthalamide. The differential activity of 2 between galectin-3 and its naturally derived truncated form illustrates the potential to exploit physiological changes in binding-site presentation of a lectin for selective inhibition. Synthesis of a bivalent structure 11 incorporating an R-lactosyl amide linkage led to notable activity against the two galectins noted above but not the plant toxin. In sum, the conjugation chemistry is compatible with the long-term aim to develop inhibitors with selectivity to certain members among a family of medically relevant human lectins. Inhibitory efficiency was obtained with bivalent compounds, offering the perspective to increase ligand density. Also of note for further work, finespecificity differences between homologous lectins could be exploited by respective tailoring of the structure of the headgroup, hereby reducing cross-reactivity. 1, 80.0, 78.0, 76.8, 75.6, 75.4, 72.8, 71.7, 71 3.96 (s, 1H), 3.89 (s, 2H), 3.86-3.73 (m, 6H), 3.72-3.68 (m, 1H) 127.8, 102.8, 79.7, 77.1, 78.0, 77.7, 76.5, 75.3, 75.1, 72.5, 71.7, 71.6, 71.4, 70.9, 69.2, 68.5 (each CH) 
Experimental Section
Terephthalic acid (73 mg, 0.44 mmol), amine 10 (0.558 g, 0.878 mmol), and formaldehyde (80 μL of a 37% soln, 1.023 mmol) were suspended in MeOH (13 mL) and the mixture was stirred at rt for 1 h. Methyl isocyanoacetate (80 μL, 0.878 mmol) was then added and the mixture was stirred at rt for 18 h. The reaction was then heated to 45°C for 6 h and then cooled to rt and left to stir for a further 18 h and then solvent was removed under diminished pressure. 1, 87.5, 77.8, 73.0, 75.6, 74.3, 72.7, 71.1, 70.1, 68.8 (each CH) 24 and molecular sieves 4 Å (166 mg) were dried at high vacuum for 2 h. Dry dichloromethane was then added (2 mL) and the solution was stirred for 2 h at rt. TMSOTf (1.54 μL, 8.4 μmol) was added and the mixture was stirred for 30 min at rt. Satd NaHCO 3 was then added and the stirring continued for a further 30 min. The mixture was then filtered through Celite, washing with dichloromethane (5 mL). The solvent was removed and chromatography of the residue (EtOAc-cyclohexane, 3:2) gave a protected trisaccharide intermediate (42 mg, 52%) as a white powder. This protected trisaccharide (0.966 g, 1 mmol) was dissolved in dry CH 2 Cl 2 (20 mL) under N 2 . Azidotrimethylsilane (340 μL, 2.5 mmol,) and tin(IV) chloride (60 μL, 0.5 mmol) were added and the mixture was stirred for 15 min. Solid NaHCO 3 (0.5 g) was then added and stirring continued for an additional 30 min. The reaction mixture was then diluted with dichloromethane (20 mL), washed with satd NaH-CO 3 (2 mL) and water (30 mL), dried (MgSO 4 ), and filtered, then the solvent was removed under vacuum. Chromatography of the residue (cyclohexane-EtOAc, 4:6) afforded 15 as a white solid (0.78 g, 82%); mp 104°C; [R] 
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(d, J = 7.8 Hz, 2H), 4.25 (d, J = 10.5 Hz, 2H), 3.37-4.00 (m, 32H); 13 C NMR (100 MHz, CDCl 3 ) δ (ppm) 173.7 (CO), 139.3 (C), 130.8, 105.8, 105.2, 82.8, 81.3, 79.5, 79.3, 78.2, 77.6, 77.1, 75.6, 75.4, 74.5, 73.8 1, 96.9, 75.6, 73.0, 72.7, 72.4, 72.2, 71.1, 70.7, 70.4, 69.0 (each CH), 62.8, 61.8, 60 .9 (each CH 2 ), 55.6 (CH), 20.9, 20.8, 20.7, 20.6 
Trisaccharide 17 (1.17 g, 1.00 mmol) was dissolved in acetic anhydride (10 mL) and an acetic anhydride-sulfuric acid mixture (1:50, 20 mL) was added and the mixture was stirred for 2 h at rt. Dichloromethane was then added (100 mL) and the organic layer washed with water (100 mL), satd NaHCO 3 (100 mL), and water (100 mL), dried (MgSO 4 ), and filtered. The solvent was removed under diminished pressure. Chromatography of the residue (cyclohexane-EtOAc, 7:3) gave the glycosyl acetate intermediate as a white solid (0.81 g, 70%). Reaction of this glycosyl acetate (0.8 g, 0.69 mmol) with azidotrimethylsilane (0.4 g, 3.45 mmol) and SnCl 4 as described for the preparation of 15 gave the title compound (0.6 g, 77%); mp 102°C; [R] 20 D þ7 (c 0.3, CH 2 Cl 2 ); 1 H NMR (300 MHz, CDCl 3 ) δ (ppm) 8.09 (d, J = 7.2 Hz, 2H), 8.00 (d, d, J = 7.2 Hz, 2H), 7.91 (d, J = 7.2 Hz, 2H), 7.63 (m, 1H), 4H), 4H), 5.75 (t, J = 9.3 Hz, 1H) 170.4, 170.2, 170.1, 170.0, 169.8, 169.6, 169.0, 166.0, 165.2, 165.0, 133.6 (each C), 101.0, 100.3, 88.0, 76.1, 75.6, 75.3, 72.9 (2s), 72.8, 72.0, 71.5, 71.0, 70.7, 69.0, 66.6 (each CH), 62.4, 61.8, 60.8 (each CH 2 ), 20.9, 20.8, 20.7, 20.6 (each CH 3 This intermediate (23.5 mg, 10 μmol) was dissolved in dry MeOH (1 mL). Potassium carbonate was then added (15 mg), and the resulting solution was stirred for 20 h at rt. The solvent was removed under reduced pressure and water was added (2 mL). Amberlite IR-120(plus) was added, until the pH reached 6. Water was then removed by lyophilization to obtain 4 (white powder) in quantitative yield; mp 187°C; [R] 173.8, 139.4 (each C), 130.8, 105.8, 105.2, 82.0, 81.0, 80.8, 79.4, 78.2, 77.9, 77.7, 77.0, 75.7, 75.4, 74.4, 73.8, 71.4 (each CH), 63.9, 62.8, 62.7 (each CH 2 8, 165.5, 165.4, 165.3, 165.2, 164.8 (2s) (each C), 133.5, 133.4 (2s), 133.3, 133.2, 129.7 (4s), 129.6 (2s), 129.5, 129.4 (2s), 129.1, 128.9, 128.7, 128.6 (3s), 128.5, 128.3, 128.2 (each CH), 111.9, 108.5 (each C), 104.9, 101.1, 99.8, 82.7, 81.4, 80.4, 75.9, 73.4, 73.0, 72.7, 71.7 (2s), 71.4, 69.9, 67.5 (each CH), 67.0, 66.1, 62.0 (each CH 2 ), 26.6, 26.5, 25.9, 25.0 (each CH 3 ) ; IR (KBr) 3064, 2985, 1730, 1603, 1453, 1269, 1093 , 1070 cm 
. This intermediate was dissolved in pyridine (5 mL) and acetic anhydride (5 mL) and the mixture was stirred for 15 h. The volatile reagents were removed and toluene (2 Â 10 mL) and CH 2 Cl 2 (2 Â 10 mL) were evaporated from the residue. Chromatography (cyclohexane-EtOAc, gradient elution, 3.5:1 to 1:1) gave the protected glycosyl acetate intermediate as a white amorphous solid (0.51 g, 81% over two steps, mixture of anomers, R:β= 3:2). Reaction of this glycosyl acetate (0.492 g, 0.351 mmol) with azidotrimethylsilane (0.155 mL, 0.878 mmol) as described for preparation of 15 gave, after chromatography (cycohexane-EtOAc, gradient elution, 3:1 to 1:1), the glycosyl azide precursor to 22 as a white foam (0.294 g, 61%). Catalytic hydrogenation of this glycosyl azide (0.252 g, 0.182 mmol) as described for 15 gave, after chromatography (cyclohexaneEtOAc, 1:1 to EtOAc-CH 2 Cl 2 , 9:1), 22 as a white foam (0.179 g, 72%); R f 0.44 (EtOAc-CH 2 Cl 2 , 9:1); [R] 3H), 14H), 7.20 (t, J = 7.9 Hz, 2H), 7.13 (t, J = 7.8 Hz, 2H) 0, 169.7, 168.4, 165.9, 165.8, 165.7, 165.6, 165.5, 165.4, 165.0 (each C), 133.9, 133.8 (2s), 133.7, 133.5 (2s), 13.4, 130.2, 130.1, 130.0, 129.9 (3s) (each CH), 129.7 (CH), 129.7 (2s), 129.5, 129.1 (each C), 128.9 (each CH), 128.9 (C), 128.8 (CH), 128.8 (C), 128.5 (2s), 128.4 (each CH), 101.4, 101.2, 85.4, 79.5, 75.9, 73.9, 73.3, 73.1, 73.0, 72.2, 72.0, 71.7, 70.2, 68.7, 67.8 
Reaction of the amine 22 (48.5 mg, 0.036 mmol) with terephthaloyl chloride as described for 10 gave, after chromatography (EtOAc-cyclohexane, gradient elution, 1:1 to 3:2), the protected diamide as a white amorphous solid (28.6 mg, 56%). Deprotection of the diamide (27 mg, 0.01 mmol) with the Zempl en procedure gave 5 (5.6 mg, 52%) as a white solid after semipreparative HPLC; [R] 1, 103.2, 102.8, 80.0, 85.2, 78.6, 77.7, 75.6, 75.1, 74.5, 73.4, 72.8, 71.7, 71.2, 68.8, 68.0 (each CH), 61.3, 60.8, 60.3 (0.745 g, 2.18 mmol) as described for 13 gave, after chromatography (cyclohexane-toluene-EtOAc, 3:2:1), the glycosidic product as a white foam (0.62 g, 33%). To this intermediate (0.264 g, 0.189 mmol) in dry CH 3 CN (2 mL) at 0°C were added Pd(Ph 3 ) 4 (0.022 g, 0.019 mmol) and pyrrolidine (0.016 mL, 0.189 mmol), respectively, with stirring for 1 h. The mixture was then filtered through Celite and the solvent was removed. The residue was dissolved in EtOAc and the organic layer was washed with H 2 O (2 Â 15 mL). The water layer was then washed with EtOAc (3 Â 15 mL) and the organic layers combined, dried (MgSO 4 ), and filtered, then solvent was removed under diminished pressure to give 25 (0.238 g, 92%) ; [R] 132.1 (2s), 131.9 (2s) , 129.9, 129.8, 129.7 (2s), 129.6 (2s), 129.5 (each CH), 129.5, 129.4, 129.3, 128.9 (each C), 128.7 (CH), 128.7 (C), 128.6, 128.5 (2s), 128.4, 128.2, 79.0, 76.0, 75.5, 73.0, 72.8, 72.0, 71.9, 71.7, 71.4, 69.9, 69.5, 67.5 1, -β-D-glucopyranosyl)-(1f3)-1-azido-1-deoxy-β-D-glucopyranuronamidomethyl]benzene 6. Acid 25 (117 mg, 0.88 mmol), HOBt (27 mg, 0.201 mmol), p-xylylenediamine (5 mg, 0.04 mmol), and DIPEA (0.018 mL, 0.1 mmol) were dissolved in dry DMF (0.8 mL) at 0°C under N 2 . HATU (43 mg, 0.11 mmol) was added and the reaction was stirred for 1 h at 0°C and then overnight at rt. Ethyl acetate was added and the mixture was washed with H 2 O (2 Â 10 mL), the organic layer was separated, dried (MgSO 4 ), and filtered, and the solvent was removed. Chromatography of the residue (toluene-EtOAc, 2:1) gave the intermediate protected diamide as a pale yellow solid (72 mg, 65%). To this protected diamide (33 mg, 0.012 mmol) in MeOH-CH 2 Cl 2 (2.5 mL, 4:1) was slowly added a solution of NaOMe (0.1 mL, 25 M in MeOH) and the resulting mixture was stirred for 3 h at 0°C. Solid CO 2 was added, the mixture was stirred for 20 min, and the solvent was then removed under diminished pressure. The residue was dissolved in water and then lyophilized to give 6 as a white powder. 127.7, 103.2, 102.7, 90.2, 83.4, 78.7, 76.9, 75.6, 75.1, 74.4, 73.4, 72.8, 72.5, 71.2, 69.8, 68.8 (each CH), 61.3, 60.4, 42.8 19b (940 mg, 2.61 mmol) gave allyl R-D-glucopyranosiduronic acid as a yellow foam (589 mg, 96%). This intermediate (1.56 g, 6 .30 mmol) was suspended in acetic anhydride (23 mL) in the presence of molecular sieves and stirred in a preheated bath at 85°C for 2 h. The solvent was coevaporated with toluene to give a brown oil that was dried under high vacuum. The oil was dissolved in cyclohexane-EtOAc (1:1) then filtered, and the filtrate was passed through a short column of silica gel eluting with cyclohexane-EtOAc (1:1). This gave a 6,3-lactone intermediate as a yellow oil (1.63 g, 86%), which was used in the next reaction without further purification. Allyl alcohol (2.5 mL, 36.7 mmol) was added to a solution of the 6,3 lactone intermediate (1.63 g, 5.33 mmol) in dry THF (8 mL) in the presence of NaOAc (217 mg, 2.65 mmol) and molecular sieves at rt and under N 2 . The mixture was stirred at rt for 24 h then filtered, and the filtrate was evaporated under reduced pressure to give a brown oil. This oil was dissolved in dichloromethane (30 mL) and washed with brine. The aq phase was further extracted with dichloromethane (2 Â 15 mL) and the combined organic extracts were dried (MgSO 4 ) and filtered, then the solvent was removed under reduced pressure. Chromatography of the residue (cyclohexane-EtOAc, 2:1) gave 28 as a white solid (1. 2H), J = 10.2, 1H), J = 9.6 Hz, 2H), 1H, ) 2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl-(1f4)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyl-(1f3)-2,4-di-O-acetyl-1-Oallyl-r-D-glucopyranuronic Acid 29. Glycoside coupling reaction of acceptor 28 (1.31 g, 3.65 mmol) and trichloroacetimidate 19 (3.22 g, 2.65 mmol) as described for 13 gave, after chromatography (eluant cyclohexane-toluene-EtOAc 3:2:1 to 5:4:2), the protected trisaccharide intermediate as a white solid (3.11 g, 83%) . To this protected trisaccharide (1.45 g, 1.027 mmol) in dry acetonitrile (8 mL), cooled on an ice bath and under N 2 , tetrakis(triphenylphosphine)palladium (117 mg, 0.10 mmol) was added followed by pyrrolidine (85 μL, 1.032 mmol). The reaction mixture was stirred on an ice bath for 1 h and then the solvent was removed under diminished pressure. The residue was dissolved in dichloromethane and washed with 0.1 M HCl and brine and then dried (MgSO 4 ) and filtered, then the solvent was removed under diminished pressure. The residue was filtered through a short column of silica gel (eluant: dichloromethane then MeOH) to give 29 as a pale yellow solid (980 mg, 70%); R f 0.15 (dichloromethaneMeOH, 95:5); [R] 
